Margaret Olinger

Chief Commercial Officer at Amylyx

Margaret Olinger joins Amylyx after more than a decade at Alexion Pharmaceuticals, where she helped build and lead some of the most successful commercial launches and operations throughout the U.S. and globally for therapies addressing unmet needs in rare and ultra-rare diseases, including Strensiq® and Soliris®. During Ms. Olinger’s tenure at Alexion, she served in various commercial leadership roles, most recently as vice president, head of global Strensiq® therapeutic area, and previously held positions including vice president, U.S. complement business unit leader; vice president, global hematology therapeutic area; vice president, global PNH therapeutic area; and vice president, U.S. and global marketing, a role in which she supported commercialization of Soliris® for PNH across all markets. Prior to Alexion, Ms. Olinger spent nearly 20 years at Bayer Healthcare, serving in various leadership and commercial positions, which culminated in her role as director, executive operations. Ms. Olinger received a Bachelor of Science in Business Administration from Albertus Magnus College and a Master of Business Administration from the University of New Haven.


  • Chief Commercial Officer

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.